Holds one active US DMF and one valid CEP for heparin, filing since 2011. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF and one valid CEP for heparin, filing since 2005. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 5 markets.
Holds one active US DMF for heparin, filing since 2005. Its 2025 FDA inspection closed as NAI.
Holds one active US DMF for heparin, filing since 2009. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for heparin, filing since 2016. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for heparin, filing since 2009. Its 2018 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for heparin, filing since 2004. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for heparin, filing since 2008. Its 2015 FDA inspection closed as NAI.
The names are listed below. The filings, inspection history and GMP certificates behind each one are available with a free account.
This page filters the worldwide Heparin manufacturer list to companies based in China. The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Read the full method.
Tell us which markets you need to file in. These suppliers come back tiered for those markets, with the price corridor and an RFI sheet.
Start for free